Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AssigneeAmarin Pharmaceuticals Ireland Limited
InventorsMehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00% 8.50% or at least about 6.8%.
Claims15
A method of treating or preventing a cardiovascular disease in a subject having diabetes or at risk of developing diabetes, the method comprising administering to the subject a pharmaceutical composition comprising about 4 g of eicosapentaenoic acid ethyl ester per day, wherein the pharmaceutical composition is administered to the subject for a period of time effective to reduce a baseline hemoglobin A1c (HbA1c) level and/or baseline high-sensitivity C reactive protein (hs-CRP) level in the subject.
Dependencies are inferred from the claim text.